New Generation Antiparasitics: Safety Profiles for MDR1 Dogs

For years, the conversation about parasite prevention in MDR1-affected dogs has been dominated by the same question: which macrocyclic lactones are safe at which doses? The arrival of the isoxazoline class of antiparasitics has fundamentally changed that conversation. For the first time, we have highly effective flea and tick preventatives that work through a completely different mechanism than the macrocyclic lactones, and more importantly, that do not appear to interact with P-glycoprotein in any clinically significant way.

This is genuinely good news for owners of MDR1-affected dogs. But it comes with nuance that matters. Not all new-generation products are created equal when it comes to MDR1 safety, and some combination products mix isoxazolines with macrocyclic lactones, which reintroduces the very risk these owners are trying to avoid. Understanding exactly what is in each product and how it interacts with the MDR1 mutation is essential for making safe choices.

The Isoxazoline Revolution

The isoxazoline class includes afoxolaner (NexGard), fluralaner (Bravecto), sarolaner (Simparica), and lotilaner (Credelio). These drugs work by blocking glutamate-gated chloride channels and gamma-aminobutyric acid (GABA) receptors in arthropod nervous systems, causing uncontrolled neural activity and death in fleas and ticks. This mechanism is entirely distinct from the macrocyclic lactones, which also target glutamate-gated chloride channels but through a different binding site and with significantly more cross-reactivity with mammalian receptors.

The critical distinction for MDR1-affected dogs is that isoxazolines are not significant substrates for P-glycoprotein. They do not rely on the P-glycoprotein efflux pump for removal from the brain. They are metabolized primarily through the liver via cytochrome P450 enzymes, and their distribution into the central nervous system appears to be limited by mechanisms independent of the blood-brain barrier P-glycoprotein pump.

This means that in theory, and increasingly in practice, these drugs should be equally safe in MDR1-affected dogs and normal dogs. The defective P-glycoprotein pump that makes ivermectin so dangerous for these dogs does not play a meaningful role in isoxazoline pharmacokinetics. To understand why the P-glycoprotein difference matters so profoundly, our article on the mechanism behind MDR1 toxicity explains the molecular pathways in detail.

What the Evidence Shows

Safety data for isoxazolines in MDR1-affected dogs has accumulated steadily since these products first reached the market. Here is what we know for each major product.

Afoxolaner (NexGard)

NexGard was the first oral isoxazoline approved for dogs. Safety studies included Collies and other herding breeds, though not all studies specifically stratified results by MDR1 genotype. Post-market surveillance data and published case series have shown no increased adverse event rate in MDR1-affected dogs compared to the general dog population.

The most commonly reported side effects in all dogs include vomiting, diarrhea, lethargy, and decreased appetite. These occur at similar rates regardless of MDR1 status. The seizure risk noted on NexGard's label applies to all dogs and appears to be related to the drug's mechanism of action on neural chloride channels rather than P-glycoprotein transport.

Fluralaner (Bravecto)

Bravecto, available as both an oral chew and a topical solution, provides 12 weeks of flea and tick protection per dose. Its safety profile in MDR1-affected dogs has been specifically studied. A 2019 study examined fluralaner at up to five times the label dose in Collies with confirmed MDR1 homozygous mutations. No neurological signs attributable to the drug were observed at any dose level.

This five-times-dose safety margin in MDR1 homozygous dogs is significant. For comparison, ivermectin causes severe toxicity in these same dogs at doses only modestly above the heartworm prevention level. The fact that fluralaner shows no increased toxicity even at massive overdose in the most sensitive dogs provides strong evidence that P-glycoprotein is not a critical factor in its disposition.

Sarolaner (Simparica)

Simparica has demonstrated safety in herding breeds in both pre-approval and post-market studies. Like the other isoxazolines, it does not appear to be a significant P-glycoprotein substrate. The label includes a seizure warning applicable to all dogs, particularly those with a history of seizure disorders.

It is worth noting that Simparica Trio, the combination product, adds moxidectin for heartworm prevention. Moxidectin is a macrocyclic lactone and a P-glycoprotein substrate. This means Simparica alone is likely safe for MDR1 dogs, but Simparica Trio reintroduces the macrocyclic lactone concern and must be evaluated with the same caution as any moxidectin-containing product.

Lotilaner (Credelio)

Credelio is the newest isoxazoline in widespread use. Published safety data in MDR1-affected dogs is more limited than for the older products, but the available evidence follows the same pattern. No increased adverse event rate in herding breeds, and the pharmacological profile suggests no significant P-glycoprotein interaction.

The Combination Product Trap

This is where many owners and some veterinarians get confused. The trend in veterinary parasitology is toward all-in-one products that cover fleas, ticks, heartworm, and intestinal parasites in a single monthly dose. These products are convenient and improve compliance, both legitimate benefits. But for MDR1-affected dogs, they can be dangerous precisely because they combine safe ingredients with potentially unsafe ones.

Simparica Trio combines sarolaner (isoxazoline, likely safe for MDR1 dogs) with moxidectin (macrocyclic lactone, P-glycoprotein substrate) and pyrantel (not a P-glycoprotein substrate, safe). The moxidectin component at the heartworm prevention dose is probably safe for most MDR1-affected dogs, similar to how low-dose ivermectin in Heartgard is generally tolerated. But it deserves the same careful consideration as any macrocyclic lactone product.

The key is reading labels carefully. Do not assume that because a product contains an isoxazoline, everything in it is safe for MDR1 dogs. Look at every active ingredient. If there is a macrocyclic lactone component, evaluate it independently using the same risk assessment you would apply to any macrocyclic lactone product. Our guide on macrocyclic lactones to avoid provides the framework for that assessment.

Beyond Isoxazolines: Other Modern Options

The isoxazolines are not the only new-generation antiparasitics relevant to MDR1-affected dogs. Several other products and drug classes deserve evaluation.

Emodepside

Emodepside is a novel anthelmintic available in some markets in combination with praziquantel (Profender). It works through a unique mechanism involving presynaptic latrophilin receptors. Early studies suggest it is a P-glycoprotein substrate, which means MDR1-affected dogs could be at increased risk for adverse effects. Until more data is available, I recommend caution with emodepside in MDR1-positive dogs.

Spinosad

Spinosad (Comfortis) is an oral flea preventative derived from a naturally occurring soil organism. It works by activating nicotinic acetylcholine receptors in insects. It does not appear to be a significant P-glycoprotein substrate and has been used in herding breeds without increased adverse event reporting. It can be considered a safe flea-only option for MDR1-affected dogs, though it provides no tick or heartworm protection.

Topical Permethrin Products

Permethrin-based topical products (K9 Advantix, various generic products) work through a different mechanism entirely and are not P-glycoprotein substrates. They are safe for MDR1-affected dogs from a drug sensitivity perspective. The standard caution with permethrin products regarding cat toxicity applies regardless of MDR1 status. Never use permethrin products on dogs that live with cats unless you can prevent all feline contact with the treated dog for at least 48 hours.

Fenbendazole

Fenbendazole (Panacur) is a benzimidazole anthelmintic that has been used safely in MDR1-affected dogs for decades. It is not a P-glycoprotein substrate and can be used at standard doses for intestinal parasite treatment. It remains an excellent choice when deworming is needed in dogs where macrocyclic lactones are contraindicated.

Building a Complete Parasite Prevention Protocol

With the isoxazolines now available for flea and tick prevention and several safe options for intestinal parasites, building a comprehensive parasite prevention protocol for MDR1-affected dogs has become much simpler than it was a decade ago. Here is how I approach it.

Flea and Tick Prevention

Any isoxazoline product (NexGard, Bravecto, Simparica, Credelio) can be used at standard label doses. Choose based on your preference for monthly versus extended dosing intervals, additional tick species coverage, and your dog's individual tolerance. Start with one product and monitor for the first 48 hours after the initial dose, just as you would with any new medication.

Heartworm Prevention

This remains the one area where macrocyclic lactones are essentially unavoidable. Low-dose ivermectin (Heartgard) and milbemycin (Interceptor) have strong safety records at heartworm prevention doses in MDR1-affected dogs. Choose one of these products dosed accurately for your dog's body weight. For detailed guidance on selecting the best heartworm preventative, see our heartworm prevention guide for sensitive breeds.

Intestinal Parasite Control

Fenbendazole and pyrantel are both safe for MDR1-affected dogs. If your heartworm product includes pyrantel (as in Heartgard Plus), that covers hookworms and roundworms. Periodic fenbendazole treatment can address whipworms and other intestinal parasites as needed based on fecal testing.

The Seizure Question

All isoxazolines carry label warnings about potential seizure risk, which understandably concerns owners of MDR1-affected dogs. It is important to understand what this warning means and does not mean in the context of MDR1.

The seizure risk with isoxazolines is related to their mechanism of action on neural chloride channels, the same mechanism that kills fleas and ticks. At approved doses, the concentration in the mammalian brain is extremely low and not sufficient to cause neural effects in the vast majority of dogs. However, dogs with pre-existing seizure disorders may have a lower threshold, and rare idiosyncratic reactions can occur.

This seizure risk is independent of MDR1 status. It does not represent P-glycoprotein-mediated drug accumulation in the brain, which is the mechanism behind ivermectin toxicity. An MDR1-affected dog is not at higher seizure risk from isoxazolines than a normal dog. However, if your MDR1-affected dog also has a seizure disorder, discuss all antiparasitic options with your neurologist before starting any new product.

What to Watch For

Even with drugs that are generally safe for MDR1-affected dogs, individual reactions can occur. After starting any new antiparasitic, monitor your dog for 24 to 48 hours. Watch for excessive drooling, vomiting, diarrhea, lethargy, tremors, stumbling, or any behavioral changes. These signs could indicate an individual sensitivity unrelated to MDR1, a concurrent illness, or in rare cases, an unexpected drug interaction.

Report any adverse effects to your veterinarian and to the product manufacturer. Post-market surveillance depends on owner and veterinarian reports to identify rare adverse effects. The more data we collect, the better we understand these drugs' safety profiles across all genetic backgrounds.

The Bigger Picture

The development of the isoxazoline class represents a genuine breakthrough for MDR1-affected dogs. For the first time, owners of drug-sensitive breeds have access to highly effective flea and tick preventatives that do not carry the macrocyclic lactone risk. Combined with the established safety of low-dose heartworm preventatives and non-macrocyclic lactone dewormers, it is now possible to provide comprehensive parasite protection without meaningful MDR1-related risk.

This was not the case fifteen years ago. Owners of MDR1-affected dogs faced genuinely difficult choices about parasite prevention, sometimes accepting suboptimal protection because the safest options were also the least effective. Those days are largely behind us. For owners who travel internationally with their MDR1 dogs, packing isoxazoline products from home eliminates the risk of encountering only macrocyclic lactone-based options abroad. For broader context on how MDR1 affects drug choices across every category, the comprehensive drug avoidance list at MDR1 Gene Guide provides an excellent cross-reference.

As veterinary pharmacology continues to advance, I expect we will see more drug classes developed that work through mechanisms independent of P-glycoprotein. Similar progress is being made in veterinary oncology, where researchers are refining chemotherapy protocols specifically for MDR1-affected dogs to maximize efficacy while minimizing the toxicity risks created by absent P-glycoprotein function. Each new class gives us additional tools for protecting these genetically vulnerable dogs. In the meantime, the tools we have today, used with knowledge and care, are more than sufficient to keep MDR1-affected dogs parasite-free and safe.